CIC
What's Inside


College Links

 About

 Directory

 Employment

 Map/Directions

 Volunteer

Search

 

 

Make a Gift box


 

 
  Home > Current Clinical Trials > Oncology
 

Oncology

PUB/CVM/CIC/AmberLuke

Welcome to the Oncology Clinical Trials Page!

The following studies are currently recruiting patients. Click on the study name for full information below:

SRCBST: dose-finding for a ligand targeted toxin to treat hemangiosarcoma 

To find out how to donate samples for veterinary oncology research, see Modiano Lab Study Info.
 



SRCBST2: dose-finding for a ligand targeted toxin to treat hemangiosarcoma 

Current Status: Active and enrolling
Principal Investigator: Jaime Modiano, VMD, PhD,
Contacts: Dr. Modiano: modiano@umn.edu
Amber Winter, study technician: 612-624-1352 or alwinter@umn.edu
Oncology service at 612-626-8387 (main VMC number) 

The study: SRCBST2 is a continuation of the first SRCBST study. The first 21 dogs with hemangiosarcoma treated in the SRCBST trial showed that the drug is safe and doubles the expected survival time.  This significant gain in the treatment for this disease is encouraging, and it strengthens our resolve to continue our efforts to improve survival and maintain quality of life for dogs with hemangiosarcoma.

Hemangiosarcoma is a type of sarcoma that is difficult to treat because of its aggressive behavior and rapid progression after diagnosis. SRCBST is a sarcoma bispecific targeted toxin that has been shown to be safe in other species and that it can kill hemangiosarcoma cells in the laboratory. This is a dose-finding trial to determine the safest dose of SRCBST which is still effective. Results of this study will provide information to develop a therapy for both dogs and humans with this incurable disease.

Eligible dogs:

  • Hemangiosarcoma restricted to the spleen, which will be treated by removal of the spleen prior to enrollment in the study
  • If any gross metastasis are surgically removed at the time of splenectomy, dog may still be eligible
  • Adequate supply of blood cells
  • No concurrent kidney, liver, heart disease, or problems with blood clotting
  • No previous chemotherapy, no alternative medications
  • OK to be on prednisone or Non-steroidal anti-inflammatory drugs (NSAIDS)

Visits:

  • PET-CT (optional but desired): A week to two weeks after surgery, drop off dog for the day and overnight. We transport to imaging center on the Mpls campus (Center for Magnetic Resonance Research), provide anesthesia, stay with the dog during procedure, then return to VMC. Dogs stay overnight due to radioactive contrast used for the PET-CT, needs to be eliminated before the dog can go home.
  • Day 1, SRCBST treatment 1: drop off for the day, we collect blood, give first dose of SRCBST through intravenous catheter, collect small amounts of blood for following to help us assess the pharmacokinetics and drug distribution
  • Day 3, SRCBST treatment 2: Same as Day 1 but no extra blood draws, drop off for the day
  • Day 5, SRCBST treatment 3: Same as Day 1 but no extra blood draws, drop off for the day
  • Day 8, Recheck and begin chemotherapy
  • Day 21: 2nd PET-CT (if first one was done, and we saw evidence of micro-metastasis)
  • Day 25-29: second round of SRCBST treatment, coincides with 2nd round of chemotherapy
  • Chemotherapy continues for total of 5 doses, every 3 weeks
  • Day 88-92: Possible third round of SCRBST at the time of the 5th chemotherapy, depending upon restaging results (bloodwork, X-ray, ultrasound)

Costs of the study: Owners pay for splenectomy surgery (estimated $3,800-$4,600 for surgery at the VMC) and initial oncology exam fee and staging diagnostics (approx $900-$1,100). If the dog is eligible, the study reimburses the owner for prescreening chest x-rays, abdominal ultrasound, bloodwork, urinalysis, then covers PET-CT and all visits listed above. This is a $8,500 - $9,560 value. In addition, the study will cover up to $5,000 in chemotherapy costs (covers most if not all of chemotherapy depending upon the size of the dog).

To enroll or learn more about the study, please contact Amber Winter or Dr. Modiano (above).

Results of the first SRCBST study were presented on April 20, 2015 at the American Association for Cancer Research conference in Philadelphia, PA. See the poster here.

Return to top

For more information on cancer research at the College of Veterinary Medicine, please go to the Animal Cancer Care and Research site.

For information on the Oncology department at the Veterinary Medical Center, go here.

You may also Contact Us at the CIC.

 

 

Notice of Privacy Practices